Lindenhofgruppe Geschäftsbericht 2018

Thema Fachgebiet Ansprechperson Lindenhofgruppe Kooperations- partner / Sponsor Selbstwirksamkeits-Coaching, Mammakarzinom im Frühstadium - Pilotstudie Selbstwirksamkeitserwartung (SECOM-PSWE) Onkologie, Hämatologie Dr. med Christa K. Baumann ZeTuP, iOMEDICO Pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer (IBCSG 48-14 Positive). Onkologie, Hämatologie Prof. Dr. med. Markus Borner International Breast Cancer Study Group Eribulin as 1 st line treatment in elderly patients (≥ 70 years) with advanced breast cancer (SAKK25/14) Onkologie, Hämatologie Prof. Dr. med. Markus Borner Schweizerische Arbeitsgemein- schaft für Klini- sche Krebsfor- schung Prevention of Symptomatic Skeletal Events with Denosumab Administered every 4 Weeks versus every 12 in patients with bone metastases from castration resistant prostate cancer or from breast cancer (SAKK 96/12 REDUSE) Onkologie, Hämatologie Prof. Dr. med. Markus Borner Schweizerische Arbeitsgemein- schaft für Klini- sche Krebsfor- schung A phase III trial evaluating the role of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior adjuvant endocrine therapy for postmenopausal women with hormone-receptor positive, node positive early stage breast cancer (IBCSG 35-07 BIG 1-07 SOLE) Onkologie, Hämatologie Prof. Dr. med. Markus Borner International Breast Cancer Study Group A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Thera- pies for Premenopausal Women with Endocrine Responsive Breast Cancer tamoxifen versus ovarian function suppression + tamoxifen versus ovarian function suppression + exemestane (IBCSG 24-02 BIG 2-02 SOFT) Onkologie, Hämatologie Prof. Dr. med. Markus Borner International Breast Cancer Study Group A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer ovarian function suppression + tamoxifen versus ovarian function suppression + exemestane (IBCSG 25-02 BIG 3-02 TEXT) Onkologie, Hämatologie Prof. Dr. med. Markus Borner International Breast Cancer Study Group Helping Ourselves, Helping Others: The Young Women’s Breast Cancer Study (IBCSG 43-09 HoHo) Onkologie, Hämatologie Prof. Dr. med. Markus Borner International Breast Cancer Study Group Geschäftsbericht 2018 80 Lehre und Forschung